MA46543A - Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation - Google Patents

Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation

Info

Publication number: MA46543A
Authority: MA; Morocco
Prior art keywords: tgfbeta; compositions; methods; endonuclease variants; endonuclease
Prior art date: 2016-10-17

Application number

MA046543A

Other languages

English (en)

Inventor

Kyle Havens

Jordan Jarjour

Original Assignee

Bluebird Bio Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-17

Filing date

2017-10-17

Publication date

2019-08-21

2017-10-17 Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc

2019-08-21 Publication of MA46543A publication Critical patent/MA46543A/fr

Links

102000004533 Endonucleases Human genes 0.000 title 1
108010042407 Endonucleases Proteins 0.000 title 1
239000000203 mixture Substances 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/4229—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4256—Tumor associated carbohydrates
- A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Oncology (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)

MA046543A 2016-10-17 2017-10-17 Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation MA46543A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662409163P	2016-10-17	2016-10-17
US201662414260P	2016-10-28	2016-10-28

Publications (1)

Publication Number	Publication Date
MA46543A true MA46543A (fr)	2019-08-21

Family

ID=62018976

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA046543A MA46543A (fr)	2016-10-17	2017-10-17	Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation

Country Status (8)

Country	Link
US (1)	US11530395B2 (fr)
EP (1)	EP3526334A4 (fr)
JP (2)	JP7060591B2 (fr)
CN (1)	CN110050066A (fr)
AU (1)	AU2017346683B2 (fr)
CA (1)	CA3040157A1 (fr)
MA (1)	MA46543A (fr)
WO (1)	WO2018075541A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
ES2952525T3 (es)	2016-09-08	2023-11-02	2Seventy Bio Inc	Variantes de endonucleasa homing PD-1, composiciones y métodos de uso
AU2019236204B2 (en)	2018-03-15	2026-02-26	KSQ Therapeutics, Inc.	Gene-regulating compositions and methods for improved immunotherapy
CN110904045A (zh) *	2018-09-17	2020-03-24	中国科学院动物研究所	经修饰的t细胞、其制备方法及用途
US12404500B2 (en)	2018-12-10	2025-09-02	Novo Nordisk A/S	Homing endonuclease variants
AU2019395334A1 (en)	2018-12-10	2021-06-24	Regeneron Pharmaceuticals, Inc.	PDCD-1 homing endonuclease variants
AU2020265749A1 (en) *	2019-05-01	2022-01-06	Juno Therapeutics, Inc.	Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
SG11202111360YA (en) *	2019-05-01	2021-11-29	Juno Therapeutics Inc	Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
WO2023081900A1 (fr) *	2021-11-08	2023-05-11	Juno Therapeutics, Inc.	Lymphocytes t modifiés exprimant un récepteur recombiné de lymphocytes t (tcr) et systèmes et procédés apparentés

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
GB8918616D0 (en)	1989-08-15	1989-09-27	Univ Glasgow	Herpes simplex virus type 1 mutant
US5804413A (en)	1992-07-31	1998-09-08	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Herpes simplex virus strains for gene transfer
GB9415319D0 (en)	1994-07-29	1994-09-21	Medical Res Council	HSV viral vector
US5846782A (en)	1995-11-28	1998-12-08	Genvec, Inc.	Targeting adenovirus with use of constrained peptide motifs
US6093570A (en)	1995-06-07	2000-07-25	The University Of North Carolina At Chapel Hill	Helper virus-free AAV production
US6013516A (en)	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
WO1999006583A1 (fr)	1997-07-31	1999-02-11	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Vecteurs de virus d'herpes simplex (hsv) cibles
US5994136A (en)	1997-12-12	1999-11-30	Cell Genesys, Inc.	Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr)	1998-04-24	2002-08-02	Pasteur Institut	Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US6692736B2 (en)	2000-03-24	2004-02-17	Cell Genesys, Inc.	Cell-specific adenovirus vectors comprising an internal ribosome entry site
NZ522840A (en)	2000-06-01	2004-12-24	Univ North Carolina	A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
FR2872170B1 (fr)	2004-06-25	2006-11-10	Centre Nat Rech Scient Cnrse	Lentivirus non interactif et non replicatif, preparation et utilisations
US7892809B2 (en)	2004-12-15	2011-02-22	The University Of North Carolina At Chapel Hill	Chimeric vectors
CN101679959A (zh) *	2007-02-19	2010-03-24	赛莱克蒂斯公司	具有新的底物特异性的laglidadg归巢核酸内切酶变体及其用途
EP3578646A3 (fr) *	2007-10-31	2020-03-18	Precision Biosciences, Inc.	Méganucléases monocaténaires concues rationnellement contenant des séquences de reconnaissance non palindromiques
US20110239315A1 (en)	2009-01-12	2011-09-29	Ulla Bonas	Modular dna-binding domains and methods of use
EP2396343B1 (fr)	2009-02-11	2017-05-17	The University of North Carolina At Chapel Hill	Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
WO2010093966A2 (fr)	2009-02-12	2010-08-19	Fred Hutchinson Cancer Research Center	Génération d'une enzyme de césure de l'adn stimulant la conversion d'un gène spécifique d'un site à partir d'une endonucléase de ciblage
US9169494B2 (en)	2010-01-12	2015-10-27	The University Of North Carolina At Chapel Hill	Restrictive inverted terminal repeats for viral vectors
CA2788682C (fr)	2010-02-05	2019-03-05	The University Of North Carolina At Chapel Hill	Compositions et procedes d'amelioration de la transduction d'un parvovirus
WO2011156430A2 (fr) *	2010-06-07	2011-12-15	Fred Hutchinson Cancer Research Center	Génération et expression d'endonucléase i-onul génétiquement modifiée et ses homologues et utilisations
EP2680877B1 (fr)	2011-02-28	2019-07-10	Seattle Children's Research Institute	Couplage d'endonucléases avec des enzymes de traitement des extrémités favorisant la disruption génique à haut rendement
US8450107B1 (en)	2011-11-30	2013-05-28	The Broad Institute Inc.	Nucleotide-specific recognition sequences for designer TAL effectors
EP2986636B1 (fr)	2013-04-17	2018-11-14	Baylor College Of Medicine	Convertisseur de signal tgf-beta immunosuppresseur
ES2883131T3 (es) *	2013-05-29	2021-12-07	Cellectis	Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
AU2014273091B2 (en)	2013-05-31	2019-12-12	Cellectis	A LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof
CA2913871C (fr)	2013-05-31	2021-07-13	Cellectis	Endonuclease de homing de la famille laglidadg clivant le gene du recepteur aux chimiokines c-c de type 5 (ccr5) et utilisations associees
JP6543626B2 (ja)	2013-07-29	2019-07-10	ブルーバードバイオ，インコーポレイテッド	多部分シグナル伝達タンパク質およびその使用
WO2018022619A1 (fr)	2016-07-25	2018-02-01	Bluebird Bio, Inc.	Variants d'endonucléase de homing bcl11a, compositions et procédés d'utilisation
EP3500696A4 (fr)	2016-08-16	2020-04-08	Bluebird Bio, Inc.	Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
MA46059A (fr)	2016-08-23	2019-07-03	Bluebird Bio Inc	Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
ES2952525T3 (es)	2016-09-08	2023-11-02	2Seventy Bio Inc	Variantes de endonucleasa homing PD-1, composiciones y métodos de uso
AU2017342273B2 (en)	2016-10-11	2023-07-06	Regeneron Pharmaceuticals, Inc.	TCRa homing endonuclease variants

2017
- 2017-10-17 EP EP17861537.3A patent/EP3526334A4/fr active Pending
- 2017-10-17 WO PCT/US2017/057014 patent/WO2018075541A1/fr not_active Ceased
- 2017-10-17 JP JP2019520527A patent/JP7060591B2/ja active Active
- 2017-10-17 MA MA046543A patent/MA46543A/fr unknown
- 2017-10-17 AU AU2017346683A patent/AU2017346683B2/en active Active
- 2017-10-17 CA CA3040157A patent/CA3040157A1/fr active Pending
- 2017-10-17 US US16/341,228 patent/US11530395B2/en active Active
- 2017-10-17 CN CN201780076229.5A patent/CN110050066A/zh active Pending
2022
- 2022-04-14 JP JP2022066868A patent/JP2022103174A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US11530395B2 (en)	2022-12-20
EP3526334A1 (fr)	2019-08-21
WO2018075541A1 (fr)	2018-04-26
EP3526334A4 (fr)	2020-09-30
JP7060591B2 (ja)	2022-04-26
US20200123515A1 (en)	2020-04-23
AU2017346683B2 (en)	2024-04-18
JP2019535240A (ja)	2019-12-12
CN110050066A (zh)	2019-07-23
AU2017346683A1 (en)	2019-05-09
CA3040157A1 (fr)	2018-04-26
JP2022103174A (ja)	2022-07-07

Publication	Publication Date	Title
MA46389A (fr)	2019-07-17	Variants de l'endonucléase homing pd1, compositions et procédés d'utilisation
EP3704239A4 (fr)	2021-08-18	Compositions de casz et procédés d'utilisation
MA46543A (fr)	2019-08-21	Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
EP3630962A4 (fr)	2021-01-20	Variants de l'endonucléase cblb , compositions et procédés d'utilisation
EP3352774A4 (fr)	2019-04-03	Compositions de flavonoïdes et procédés d'utilisation
EP3313404A4 (fr)	2019-08-07	Compositions thérapeutiques, associations et procédés d'utilisation
EP3414321A4 (fr)	2019-07-10	Compositions améliorant vcn et procédés d'utilisation desdites compositions
EP3436048A4 (fr)	2019-11-27	Néoantigènes et leurs procédés d'utilisation
EP3435956A4 (fr)	2020-01-15	Compositions photo-stabilisées et leurs procédés d'utilisation
EP3303634A4 (fr)	2019-03-20	Variants de cas9 et procédés d'utilisation associés
EP3307762A4 (fr)	2019-02-27	Variants de cas9 rapporteurs et leurs procédés d'utilisation
EP3298168A4 (fr)	2019-02-20	Agents réducteurs stabilisés et leurs procédés d'utilisation
MA45996A (fr)	2021-06-02	Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
EP3375796A4 (fr)	2019-06-12	Copolymère et composition le contenant
EP3390624A4 (fr)	2019-07-10	Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3377612A4 (fr)	2019-07-24	Expression fonctionnelle de monooxygénases et procédés d'utilisation
EP3359523A4 (fr)	2019-07-24	Compositions d'oligonucléotides et procédés associés
EP3394065A4 (fr)	2019-07-10	Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP3303435A4 (fr)	2019-02-20	Hydrofluoroléfines et procédés d'utilisation associés
EP3319612A4 (fr)	2019-03-06	Oxystérols et leurs procédés d'utilisation
EP3319610A4 (fr)	2019-03-06	Oxystérols et leurs procédés d'utilisation
EP3341017A4 (fr)	2019-07-17	Compositions d'immunomodulation et leurs procédés d'utilisation
EP3386927A4 (fr)	2019-08-21	Compositions polymères et procédés d'utilisation
EP3490569A4 (fr)	2020-04-15	Compositions topiques et ses procédés d'utilisation
EP3302558A4 (fr)	2019-01-16	Agents anticancéreux et procédés d'utilisation